Please login to the form below

Not currently logged in
Email:
Password:

ceritinib

This page shows the latest ceritinib news and features for those working in and with pharma, biotech and healthcare.

Pfizer files third-gen ALK inhibitor for lung cancer

Pfizer files third-gen ALK inhibitor for lung cancer

Alecensa saw sales double to reach around $385m in 2017, and its ascendency also seems to have taken its toll on Novartis’ second-generation drug Zykadia (ceritinib).

Latest news

More from news
Approximately 5 fully matching, plus 26 partially matching documents found.

Latest Intelligence

  • Pharma deals during October 2014 Pharma deals during October 2014

    The phase 1/2 studies will assess Novartis' Zykadia [ceritinib], INC 280 and EGF 816 in combination with BMS's PD-1 immune checkpoint inhibitor nivolumab [Opdivo].

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Streaming Well

Streaming Well is a healthcare focused, award-winning video production company which operates in the US and Europe....

Latest intelligence

China’s clinical trial shake-up
As many of the obstacles to running clinical trials in China fall away, the country is proving to be a better research location...
Alzheimer’s disease – is Europe prepared if a breakthrough treatment becomes available?
Healthcare leaders in the European Union should begin preparing for a breakthrough now...
The UK’s new five-year pricing agreement
Pharma has agreed to capped growth again - in exchange for uptake promises...

Infographics